Your browser doesn't support javascript.
loading
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework.
Kotsopoulos, Nikos; Bento-Abreu, André; Bencina, Goran; Connolly, Mark P.
Afiliación
  • Kotsopoulos N; Health Economics, Global Market Access Solutions LLC, Mooresville, NC, USA.
  • Bento-Abreu A; Department of Economics (UoA MBA), University of Athens, Athens, Greece.
  • Bencina G; Health Economics Outcomes Research, MSD, Brussels, Belgium.
  • Connolly MP; MSD, Center for Observational and Real-World Evidence, Madrid, Spain.
Expert Rev Pharmacoecon Outcomes Res ; 24(3): 437-445, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38231471
ABSTRACT

OBJECTIVES:

A public economic framework was used to explore lifetime government costs and benefits in relation to the Pediatric Immunization Program (PIP) in Belgium based on cases and deaths averted.

METHODS:

To estimate changes in net government revenue, we developed a decision-analytic model that quantifies lifetime tax revenues and transfers based on changes in morbidity and mortality arising from Belgium's Pediatric Immunization Program (PIP). The model considered differences in incidence rates with vaccines included in Belgium's PIP compared with the pre-vaccine era. Changes in deaths and comorbid conditions attributed to PIP on the Belgium 2020 birth cohort were used to estimate gross lifetime earnings changes, tax revenue gains attributed to averted morbidity and mortality avoidance, disability transfer cost savings, and averted special education costs associated with each vaccine.

RESULTS:

Vaccinating a single birth cohort according to the PIP gives rise to fiscal gains of €56 million in averted tax revenue loss, €8 million disability savings, and €6 million special education cost-savings. Based on the costs of implementing the PIP, we estimate the fiscal benefit-cost ratio (fBCR) of €2.2 investment return for the government from every €1 invested excluding longevity costs.

CONCLUSIONS:

Reducing vaccine-preventable conditions generates tax revenue for the government, providing fiscal justification for sustained immunization investments.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Gobierno Tipo de estudio: Prognostic_studies Límite: Child / Humans País/Región como asunto: Europa Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Gobierno Tipo de estudio: Prognostic_studies Límite: Child / Humans País/Región como asunto: Europa Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido